Retreatment with Injectable Poly-l-Lactic Acid for HIV-Associated Facial Lipoatrophy
- 1 February 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Dermatologic Surgery
- Vol. 35 (Sup 1), 350-359
- https://doi.org/10.1111/j.1524-4725.2008.01047.x
Abstract
Facial lipoatrophy occurs in HIV-positive patients taking highly active antiretroviral therapy and during natural aging. Injectable poly-l-lactic acid (PLLA) is a device approved internationally for restoration and correction of the signs of HIV-associated facial lipoatrophy. To evaluate the long-term safety, duration of effect, and satisfaction with serial injections of PLLA for HIV-associated facial lipoatrophy. In this single-site, open-label, retreatment study, 65 HIV-positive patients were treated with injectable PLLA every 5 weeks (until optimal recorrection). Presenting degree of lipoatrophy based on the James scale (1=mild, 4=severe) was reviewed. Skin thickness was measured at fixed points with calipers. Patients completed a post-retreatment satisfaction questionnaire. Nearly 10% of patients had persistent correction >36 months, based on patient report. Approximately 50% required three or fewer retreatments to maintain satisfactory correction (determined by patient and physician). Milder lipoatrophy on initial presentation required fewer retreatments and had more sustained correction. Time to first retreatment varied according to James scale score: 1 (21.4 months) and 4 (13.0 months). The mean patient satisfaction score was 4.9 (1=dissatisfied, 5=very satisfied) at study end. No serious adverse events were reported. Injectable PLLA is a safe and effective long-term treatment option for HIV-associated lipoatrophy.Keywords
This publication has 13 references indexed in Scilit:
- Use of Polylactic Acid Implants to Correct Facial Lipoatrophy in Human Immunodeficiency Virus 1–Positive Individuals Receiving Combination Antiretroviral TherapyArchives of Dermatology, 2006
- Long‐term safety and efficacy of poly‐L‐lactic acid in the treatment of HIV‐related facial lipoatrophyHIV Medicine, 2006
- Facial Volumetric Correction with Injectable Poly‐l‐Lactic AcidDermatologic Surgery, 2005
- Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophyJournal of the American Academy of Dermatology, 2005
- A randomized open‐label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infectionHIV Medicine, 2004
- Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patientsAIDS, 2003
- A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individualsSexually Transmitted Infections, 2003
- Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophyAIDS, 2001
- The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO CohortJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Lipodystrophy Syndrome in Patients with HIV InfectionDrug Safety, 2001